Scientific Library
- Acute Coronary Syndrom
- ASCVD Prevention
- Bifurcation Stenting
- Cardio-Oncology
- Congestive Heart Failure
- DAPT Duration
- Drug Coated Balloon
- Fractional Flow Reserve
- IVUS Guidance
- Optical Coherence Tomography
- Pulmonary Hypertension
- Rotational Atherectomy
- Shear Stress
- Stenting Left Main
- Transcatheter Aortic Valve Replacement
- Percutaneous LAA Occlusion
- Mitral/Tricuspid Valvular Disease
- Other Relevant Articles
-
Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision MedicinePatel KV, Pandey A, de Lemos JA et al. -
Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD: The ASET Pilot StudyN Kogame, PO Guimarães, PA Lemos et al.
-
Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet SubstudyU Baber, MU Zafar, R Mehran et al.
-
A Prospective, Multicenter, Randomized, Open-label Trial to Compare Efficacy and Safety of Clopidogrel vs. Ticagrelor in Stabilized Patients with Acute Myocardial Infarction after Percutan eous Coronary Intervention: rationale and design of the TALOS-AMI trialM-W Park, CJ Kim, K Chang et al.
-
Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary InterventionDJ Angiolillo, U Baber, R Mehran et al.
-
Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCIHY Wang, RL Gao, KF Dou et al.
-
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial SubanalysisJurrienM Berg, A de Veer, the RE-DUAL PCI Steering Committee and Investigators et al.
-
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trialDewilde WJ, Oirbans T, WOEST study investigators.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
